On the other hand, in tumors that feature low CD40 expression, fail to express strong antigens, or are characterized by poor immune infiltrate, CD40 agonist therapy has shown promise as an adjunct to multiple cancer therapies, including radiation, irreversible electroporation, neoantigen vaccine, chemotherapy, FLT3L, and checkpoint blockade (69, 162, 168–171). The gene discussed is FLT3LG; the disease is cancer.